Comparative Pharmacology
Head-to-head clinical analysis: THEO DUR versus XOPENEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEO DUR versus XOPENEX.
THEO-DUR vs XOPENEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits phosphodiesterase, increasing cAMP levels; antagonizes adenosine receptors; enhances contractility of skeletal and cardiac muscle, and relaxes bronchial smooth muscle.
Selective beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP levels.
300-600 mg orally twice daily
Nebulized solution: 0.63 mg or 1.25 mg 3 times daily every 6-8 hours; metered-dose inhaler: 2 inhalations (90 mcg per inhalation) 3 times daily every 6-8 hours.
None Documented
None Documented
Terminal elimination half-life: 3-9 hours in adults (smokers: 4-5 hours; nonsmokers: 6-9 hours); 20-30 hours in premature neonates; 1-5 hours in children. Prolonged in hepatic cirrhosis, heart failure, and with CYP1A2 inhibitors.
Terminal elimination half-life: 3.3-4.0 hours in adults. Clinically, twice-daily dosing is not recommended due to shorter half-life; every 4-6 hour dosing is standard for acute bronchodilation.
Primarily hepatic metabolism by CYP1A2 and CYP3A4; renal excretion of unchanged drug accounts for approximately 10% in adults, up to 50% in neonates; biliary/fecal excretion negligible.
Renal: 80-100% as unchanged drug and metabolites (approximately 60% as unchanged levalbuterol, 20% as inactive sulfate conjugate). Fecal: <5%.
Category C
Category C
Bronchodilator
Bronchodilator